OCULAR

OCULAR

DEVELOPING AN EFFICIENT OPHTHALMIC DEVICE COMBINATION PRODUCT

Zoë Davidson looks at how understanding the patient journey can help develop an efficient ophthalmic device combination product.

OCULAR

ADVANCED DRUG DELIVERY FOR DRY EYE TREATMENT

Rouven Kraus and Wilfried Woesthuis discuss Aero Pump and Medspray's new open-eye spray for the treatment of dry eyes.

INTERVIEW

Dr Gautam N Shetty

Congruence Medical Solutions

INTERVIEW WITH DR SRI MUDUMBA, SANTEN & DR GAUTAM SHETTY, CONGRUENCE

In this interview, Dr Sri Mudumba, Santen, and Dr Gautam N Shetty, Congruence Medical Solutions, share insights from their experience of working together in developing the MDS for ophthalmic injections.

EXPERT VIEW

Dr Barbara Morgan

OPTIMISING OPHTHALMIC DRUG DELIVERY FOR THERAPEUTIC EFFECTIVENESS

Barbara Morgan discusses how eye physiology impacts product formulation and choice of dosage form, and how advanced delivery technologies are providing new options for formulators seeking to improve the bioavailability or stability of their ophthalmic treatments.

OCULAR

Matthias Birkhoff

Aptar Pharma

DELIVERING ON THE GROWING NEED FOR TOPICAL PRESERVATIVE-FREE OPHTHALMIC TREATMENTS

Matthias Birkhoff provides an overview of existing ophthalmic delivery technologies and progress made within topically applied medications – and introduces a new market standard for testing microbial integrity in preservative-free formulation.

CONNECTIVITY

Marcus Bates

Aptar Pharma

THE CURRENT STATE OF PLAY IN CONNECTED DEVICES

Marcus Bates; Joachim Koerner and Jerôme Prraquin discuss the current state of play, what connected device advocates are doing to enable faster implementation, and how we can optimise connected technology while reducing the cost and improving human factors.

OCULAR

Thomas Grinnan

Silgan Dispensing

USING MARKET RESEARCH TO CREATE A PRESERVATIVE-FREE MULTIDOSE EYEDROPPER

Thomas Grinnan and Ralf Hergenröther explain how extensive market research and consumer testing led to the development of an eyedropper that meets patients’ and physicians’ needs for an easy-to-use device, which offers precise dosing and anti-microbial integrity.

OCULAR

Fanny Sellier

Nemera

USER TESTING: CRITICAL FOR TRULY UNDERSTANDING PATIENT NEEDS

Fanny Sellier presents a trio of comparative user studies between Nemera’s Novelia^® preservative-free, multidose eyedropper and similar products from competitors

OCULAR

Dr Gautam N Shetty

Congruence Medical Solutions

ACCURATE, PRECISE MICROLITRE DOSING WITH PREFILLABLE SYRINGES FOR OPHTHALMIC INJECTIONS

Gautam Shetty discusses the challenges inherent to delivering microlitre dosage volumes accurately from a standard prefilled syringe, and introduces Congruence’s Microlitre Dosing Syringe (MDS) platform as a solution.

OCULAR

Dr Christian Roesky

Novaliq

BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE

Christian Roesky discusses the underserved condition of dry eye disease, and presents two products in Novaliq’s pipelinefor the treatment of different types of DED.

OCULAR

Ralf Künzi

Hoffmann Neopac

KEEPING PRESERVATIVE-FREE EYEDROPS STERILE WITH THE STERIDROP™ TUBE

Ralf Künzi introduces the SteriDrop™ tube – a new multidose eyedrop delivery solution made in collaboration with Aptar Pharma.

OCULAR

Dr Jon Volmer

MedPharm

THE CHALLENGES AND OPPORTUNITIES OF DRUG DELIVERY THROUGH A COMPLEX BARRIER

Jon Volmer, Marc Brown and Jeremy Drummond discuss the development and use of advanced ex vivo and in vitro models for testing new ocular medicines to meet a growing unmet need.

EARLY INSIGHT

Frazer P Coutinho

BOTU

TARGETING DRUGS TO DISEASED OCULAR CELLS

Frazer Coutinho, Colin Green and Ilva Rupenthal discuss the targeted delivery of ocular therapeutics to diseased cells, using the cell-penetrating peptide, Xentry.

EXPERT VIEW

Douglas Cusato

INTRAVITREAL INJECTION OF VEGF INHIBITORS – IMPACT OF DRUG CONTAINERS

With the increasing use of intravitreal injections of vascular endothelial growth factor inhibitors in the treatment of numerous serious ocular diseases, Douglas Cusato provides a detailed comparative analysis of the issues at play.

OCULAR

Dr Peter Noymer

Kedalion Therapeutics

ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA

Peter Noymer, Ehud Ivri, Reynaldo Quintana and Mark Blumenkranz introduce AcuStream, a novel device for next-generation delivery of topical ophthalmic delivery via an aim-assisted stream.

OCULAR

Rouven Kraus

Aero Pump

TRENDS IN ANTI-GLAUCOMA TOPICAL TREATMENTS

Rouven Kraus presents the case for multidose delivery systems rather than single-use disposables, and introduces Aero Pump’s Ophthalmic Multidose System.

CONNECTIVITY

Nemera

EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY

Nemera introduces the e-Novelia® and e-Advancia® add-ons for ophthalmic and nasal devices.

PREFILLED SYRINGES

Alessio Bonati

SG Ompi

AN OPTIMISED PLATFORM FOR HIGHLY SENSITIVE BIOLOGICS

Alessio Bonati discusses the problematic interactions between drugs and their primary containers and goes on to introduce the Alba platform, Ompi’s range of primary glass containers designed to unify drug-container interactions over a product’s lifecycle.

OCULAR

Dr Shikha P Barman

Integral BioSystems

SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE

Shikha Barman reviews approaches for delivering drugs for diseases of the back of the eye, and introduces EySite-InjecT^™.

OCULAR

Dr Christian Roesky

Novaliq

AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY

Traditional aqueous vehicles for topical ophthalmic medications suffer from a number of limitations. Christian Roesky reviews the benefits of EyeSol®, a proprietary aqueous-free drug delivery technology.

INTERVIEW

Fanny Sellier

Nemera

FANNY SELLIER, NEMERA

Talking here with ONDrugDelivery Magazine, Ms Sellier discusses Nemera’s multidose eyedropper system Novelia® for preservative-free formulations. She explains how this platform has been developed to improve patients’ lives.

EXPERT VIEW

Dr Paul Kippax

PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS

Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.

EXPERT VIEW

Di Huang

USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY

Di Huang, Erica Chen and Ilva Rupenthal discuss the possibilities offered by physical force-based methods of enhancing the efficacy of ophthalmic drug delivery by providing a way past the eye’s natural barriers.

EXPERT VIEW

Michael O'Rourke

SUSTAINED RELEASE OCULAR THERAPEUTICS

Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.

OCULAR

Dr Raj Thakur

Re-Vana Therapeutics

BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY

Raj Thakur and Prof David Jones discuss the difficulty of treating diseases of the back and front of the eye, and introduce a possible solution: OcuLief™ and EyeLief™, Re-Vana’s two proprietary sustained-release platforms.

OCULAR

Dr Patricia Zilliox

Eyevensys

CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE

Patricia Zilliox discusses the inherent difficulties in drug delivery to the back of the eye and how this creates an unmet need in ophthalmology. Dr Zilliox goes on to describe Eyevensys’ novel solution to this problem, and the company’s first lead product, EYS606.

OCULAR

Anne Brody Rubin

A TOPICAL OCULAR RING DESIGNED TO REPLACE GLAUCOMA EYE DROPS

Anne Brody Rubin introduces ForSight VISION5's ring-shaped ocular insert containing prostaglandin for the lowering of intra-ocular pressure in glaucoma.

OCULAR

Dr Paul Seaman

Midatech Pharma

OPSISPORIN: A LONG-ACTING DRUG DELIVERY APPROACH FOR UVEITIS

Here, Paul Seaman and Daniel Palmer discuss Midatech Pharma’s next generation treatments for auto-immune ocular diseases, which use a combination of innovative, sustained-release drug products.

OCULAR

Dr Mika Jokinen

DelSiTech Ltd

NEW SOLUTIONS FOR OPHTHALMIC DRUG DELIVERY USING BIODEGRADABLE SILICA MATRIX

Mika Jokinen, Cora Griffin, and Lasse Leino, PhD describe the novel opportunities that biodegradable silica matrix technology offers to ophthalmic drug delivery.

OCULAR

Robin de Bruijn

EmulTech

IMPROVING OPHTHALMIC DRUG DELIVERY WITH NOVEL EMULSION TECHNOLOGIES

Robin de Bruijn and Frank de Jong describe EmulTech’s ET4ME micro-encapsulation process, and its suitability as a particle formation technology for enhancing and enabling ophthalmic injectables.

OCULAR

Fanny Sellier

Nemera

USING INTELLIGENT DESIGN TO DELIVER SAFE MULTI-DOSE EYE DROPS

Ms Fanny Sellier, explains how the intelligent design of multi-dose bottles provides a viable means of delivering safe, preservative-free eye drops.

EXPERT VIEW

Michael O'Rourke

SUSTAINED-RELEASE OCULAR DELIVERY TECHNOLOGIES

Michael O'Rourke discusses the advances in the development and launching of sustained-release ocular drug delivery systems seen in recent years.

OCULAR

Donna Bibber

Micro Engineering Solutions

SCALEABILITY OF MICRO INTRAOCULAR IMPLANTS AND DEVICES

Donna Bibber discusses some of these micro-intraocular implants and devices and the scalability challenges associated with each, from the perspective of a plastics engineer.

OCULAR

Chris Muller

Mati Therapeutics

THERAPY WITHOUT DROPS: A REALITY

Chris Muller and Deepank Utkhede introduce Mati Therapeutics' Evolute^® ocular delivery system, a non-invasive, sustained-release platform that combines a novel punctal plug with a sustained release drug eluting core.

OCULAR

Dr Shikha P Barman

Integral BioSystems

INTRODUCING OCUSURF™ NANOSTRUCTURED EMULSION AS A 505(B)(2) STRATEGY

Shikha P Barman describes how Integral Biosystems is developing a series of ophthalmic products with its OcuSurf platform.

OCULAR

Dr Paul Ashton

EyePoint Pharmaceuticals

PSIVIDA AND OPHTHALMIC DRUG DELIVERY

Paul Ashton describes how much of the progress that has been made recently in the treatment of ophthalmic diseases can be ascribed to effective drug delivery systems, and outlines some of the delivery technologies and resulting products for which pSivida has been responsible.

OCULAR

Dr Marc Horner

ANSYS, Inc

MODELLING OCULAR DELIVERY USING COMPUTATIONAL FLUID DYNAMICS

Paul Missel and Marc Horner describe the use of computational fluid dynamics simulations to predict drug flow and temperature inside the eye, and provide examples of applications modelling.

EXPERT VIEW

Dr Paul Ashton

HUGE THERAPEUTIC ADVANCES: BIGGER DRUG DELIVERY OPPORTUNITIES

Paul Ashton gives an introduction into the current state of the ophthalmics market.